Loading clinical trials...
Loading clinical trials...
A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Conditions
Interventions
Cabazitaxel
Neulasta
+2 more
Locations
3
United States
National Cancer Institute
Bethesda, Maryland, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Start Date
February 16, 2012
Primary Completion Date
August 4, 2014
Completion Date
March 30, 2017
Last Updated
May 4, 2025
NCT05987241
NCT07061964
NCT06349642
NCT07452432
NCT06668493
NCT06809140
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions